Ginkgo Bioworks Holdings Inc. (DNA)
DNA trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1830214/000162828026012346/0001628280-26-012346-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DNA on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001830214 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $170.2M |
| Net income | -$312.8M |
| Operating income | -$315.3M |
| Net margin | -183.8% |
| Operating margin | -185.3% |
| Revenue growth | -25.1% |
| Cash | $167.2M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $84.5M cash; operating cash flow -$41.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 64,825,013 (2026-10-30); 60,590,219 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | 1; latest 1-for-40 on 2024-08-20 | Source 2024-08-20 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $27.7M | -$41.0M | -$28.3M | $84.5M | No debt tags | $130.8M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $20.2M | -$46.7M | -$44.3M | $84.5M | No debt tags | $132.4M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $19.5M | -$82.6M | -$46.7M | $143.9M | No debt tags | $151.4M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $63.4M | -$80.8M | -$47.7M | $167.2M | No debt tags | $170.2M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $29.4M | -$80.8M | -$31.6M | $111.1M | No debt tags | $150.6M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $39.1M | -$60.3M | -$40.3M | $203.6M | No debt tags | $210.3M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $38.2M | -$91.0M | -$51.5M | $312.4M | No debt tags | $227.3M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $43.8M | -$107.5M | -$42.4M | $561.6M | No debt tags | $227.0M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-09-04 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.9% |
| 1 month | -18.3% |
| 3 months | +32.7% |
| Year to date | +15.6% |
| 1 year | +20.1% |
| From 52-week high | -35.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| VALN | Valneva SE | $5.65 | -0.18% | $536.1M |
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| SRZN | Surrozen Inc. | $32.32 | +2.25% | $616.1M |
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier